Hearing Toxicity of Nasopharyngeal Carcinoma After Chemoradiotherapy

Sponsor
Guangxi Medical University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05330169
Collaborator
(none)
80
18

Study Details

Study Description

Brief Summary

This observational cohort study was aimed to evaluate the hearing toxicity at multiple time points from baseline to 1 year after radical chemoradiotherapy among nasopharyngeal carcinoma patients.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    With the development of radiotherapeutic techniques and equipment as well as advances in treatment modalities, the 5-year overall survival of patients with non-disseminated NPC has exceeded 80%. However, the incidence of hearing toxicity did not decrease significantly compared with the past. The hearing loss remains the second most common toxicity after xerostomia. Audiometry, acoustic impedance testing, eustachian tube pressure measurements, and distortion product otoacoustic emissions will be used to compare hearing before treatment and up to 1 year after radical chemoradiotherapy. The related factors affecting the hearing of NPC patients will also be investigated and explored.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    80 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Prospective Observational Cohort Study to Evaluate Hearing Toxicity After Chemoradiotherapy in Patients With Nasopharyngeal Carcinoma
    Anticipated Study Start Date :
    Jul 1, 2022
    Anticipated Primary Completion Date :
    Dec 31, 2022
    Anticipated Study Completion Date :
    Dec 31, 2023

    Outcome Measures

    Primary Outcome Measures

    1. Hearing level (decibel) [up to 16 months]

      We will use pure tone audiometry to access the hearing level (decibel) before treatment and serially up to 1 year after radical chemoradiotherapy.

    2. The ratio of distortion product otoacoustic emission(DPOAE) failure [up to 16 months]

      We will use distortion product otoacoustic emission(DPOAE) to access the hearing before treatment and serially up to 1 year after radical chemoradiotherapy.

    Secondary Outcome Measures

    1. The ratio of Eustachian tube dysfuction(ETD) [up to 16 months]

      We will use eustachian tube pressure measurement to access the eustachian tube function before treatment and serially up to 1 year after radical chemoradiotherapy.

    2. Tympanogram type [up to 16 months]

      We will use acoustic impedance tests to access the tympanogram type before treatment and serially up to 1 year after radical chemoradiotherapy.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 60 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    1. Histologically confirmed non-keratinizing nasopharyngeal carcinoma(WHO II/III).

    2. About to undergo radical chemoradiotherapy with intensity-modulated radiotherapy (IMRT).

    3. Eastern Cooperative Oncology Group performance status≤1.

    4. Adequate marrow function: neutrocyte count≥1.5×10e9/L, hemoglobin

    ≥90g/L, and platelet count≥100×10e9/L.

    1. Alanine Aminotransferase (ALT)/Aspartate Aminotransferase (AST)

    ≤2.5×upper limit of normal (ULN), and bilirubin≤ 1.5×ULN.

    1. Adequate renal function: creatinine clearance rate≥ 60 ml/min (Cockcroft-Gault formula).

    2. Patients must be informed of the investigational nature of this study and give written informed consent.

    Exclusion Criteria:
    1. Age > 60 or < 18.

    2. Receiving additional targeted therapy or immunotherapy except for radiotherapy and chemotherapy.

    3. With a condition that could cause hearing impairment, such as ear canal cerumen blockage, ear canal foreign body blockage, cholesteatoma, tympanic membrane perforation, cholesteatoma otitis media, middle ear granulation tissue growth, inner ear labyrinthitis, sudden nerve deafness, Meniere's disease, acoustic neuroma, and so on.

    4. Patients who received aminoglycoside antibiotics or macrocyclic lipid antibiotics (such as streptomycin, gentamicin, kanamycin, neomycin, tobramycin, minocycline, erythromycin, roxithromycin, etc.) orally or intravenously within 30 days before treatment.

    5. Patients with hearing loss at the baseline(except for those with conductive hearing loss diagnosed by at least two deputy chief physicians as nasopharyngeal carcinoma-related)

    6. Patients who received additional treatment during the observation period due to disease progression.

    7. Pregnant or breastfeeding.

    8. Patients with prior malignancy who have received systemic chemotherapy or head and neck radiotherapy.

    9. Any other condition, including symptomatic heart failure, unstable angina, myocardial infarction, active infection requiring systemic therapy, mental illness or domestic/social factors, deemed by the investigator to be likely to interfere with a patient's ability to sign informed consent, cooperate and participate in the study, or interferes with the interpretation of the results.

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • Guangxi Medical University

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Kai Hu, professor, Guangxi Medical University
    ClinicalTrials.gov Identifier:
    NCT05330169
    Other Study ID Numbers:
    • GuangxiMUHK3
    First Posted:
    Apr 15, 2022
    Last Update Posted:
    Apr 15, 2022
    Last Verified:
    Apr 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Kai Hu, professor, Guangxi Medical University
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Apr 15, 2022